Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "A Single-Arm, Open-Label Phase 2 Trial of Doxorubicin + Zalifrelimab With Balstilimab in Pts With Advanced/Metastatic Soft Tissue Sarcomas"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Breelyn Wilky
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Breelyn Wilky
Comments 0
Login to view comments.
Click here to Login
